Outcomes-Based Contracts Aren’t So Easy, Harvard Pilgrim Cautions
This article was originally published in The Pink Sheet Daily
Value-based, risk-sharing reimbursement contracts were a hot topic at ISPOR, but Harvard Pilgrim Health Care Chief Medical Officer Michael Sherman cautioned that finding the right drug and the right pharma partner to work with are challenging.
You may also be interested in...
Pricing Pressure On Drugs To Intensify As Some Enrollee Cost-Shifting Measures Plateau – PwC
Employers’ may also look more at pitting their health plan vendors against each other for cost-saving coverage, meaning drug makers face more pressure to negotiate reimbursement and other new approaches with health plans, a PwC report suggests.
Brilinta/Bydureon’s Measurable Outcomes Are Smooth Fit For Contracts
Three-year contracts between AstraZeneca and Harvard Pilgrim focus on reduced hospitalization for Brilinta, reaching HbA1c goals for Bydureon; choosing appropriate products and outcomes are key challenge for the new reimbursement approaches.
AstraZeneca's 13 Outcomes-Based Contracts Show “Proactive" Engagement On New Models
AstraZeneca VP-Market Access Rick Suarez talks about challenges and opportunities in the emerging area of innovative outcomes-based reimbursement contracts, and specifically two new contracts with Harvard Pilgrim for Bydureon and Brilinta.